Citigroup’s ENDRA Life Sciences NDRA Stock Holding History

Citigroup’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.42K	Buy	+1,078	New	+$5.58K	﹤0.01%	5307
2026 Q1	–	Sell	-1	Closed	-$5	–	6236
2025 Q4	$5	Buy	+1	New	+$6	﹤0.01%	5862
2022 Q3	–	Sell	-1	Closed	-$7K	–	6160
2022 Q2	$7K	Buy	+1	New	+$8.94K	﹤0.01%	5502

Other funds holding NDRA

ACM

Altium Capital Management New York $68.8M AUM 7.27% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup's NDRA Position: Q3 2026 in Review

Citigroup opened a new position in ENDRA Life Sciences (NDRA) in Q3 2026: 1,078 shares worth $6.42K. The stake represents ﹤0.01% of the portfolio and ranks #5307 among its holdings. This is a return to the name: Citigroup previously reported a position in NDRA as recently as Q4 2025.

Citigroup first reported a position in NDRA in Q2 2022 and has held it in 3 quarters since. The position peaked at $7K in Q2 2022. 4 funds tracked by Wall St. Rank hold NDRA as of Q3 2026.

Citigroup held 1,078 shares of ENDRA Life Sciences worth $6.42K as of Q3 2026.
ENDRA Life Sciences was a new Citigroup position in Q3 2026.
ENDRA Life Sciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5307 holding.
Citigroup first reported a position in ENDRA Life Sciences in Q2 2022 and has held it in 3 quarters since.
Citigroup's ENDRA Life Sciences position peaked at $7K in Q2 2022.
4 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.